Baylor College of Medicine
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Baylor College of Medicine sits in the top decile of US sponsors by registered trial count (#56 of 15,742 sponsors by registered trial count).
Baylor College of Medicine: 616 sponsored US clinical trials, 93 recruiting.
Baylor College of Medicine sponsors 616 registered US clinical trials on ClinicalTrials.gov, 93 of them currently recruiting, and 376 completed. 59 of these trials are in Phase 3-4 (later-stage) and 232 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Non-Hodgkin Lymphoma, with 7 trials.
Top-decile sponsor footprint
Baylor College of Medicine ranks in the top decile of sponsors by registered trial count (#56 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
376 of 452 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (83.2%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
616 total, page 12 of 13
Effectiveness of Intensive Lipid Modification Medication in Preventing the Progression of Peripheral Arterial Disease (The ELIMIT Study)
NCT00687076
Matched Unrelated or Non-Genotype Identical Related Donor Transplantation For Chronic Granulomatous Disease
NCT00578643
Treating Late-Life Generalized Anxiety Disorder (GAD) in Primary Care
NCT00308724
Prevention of Urinary Tract Infection (UTI) in Persons With Spinal Cord Injury (SCI)
NCT00309114
Allogeneic Stem Cell Transplantation, Severe Homzygous 0/+Thalassemia or Sever Variants of Beta 0/+ Thalassemia, THALLO
NCT00578292
Diet, Exercise, Niacin, and Fenofibrate to Reduce Heart Disease Risk Factors in Individuals With HIV Lipodystrophy or Dyslipidemia
NCT00246376
Hospital-based Paraprofessional Lactation Clinic
NCT00474422
The Effect of Prolonged Pramlintide Infusion in Pediatric Diabetes
NCT00206297
LMP2a-Specific Cytotoxic T-Lymphocytes, Lymphoma (ACDAL)
NCT00082225
Use of Daclizumab for the Prevention of Allograft Rejection in Pediatric Heart Transplant Patients
NCT00284531
LMP-specific T-cells for Patients With Relapsed EBV-positive Lymphoma
NCT00062868
EBV-Specific CTLs Following CD45 Antibody to Patients With Epstein-Barr Virus (EBV) + Nasopharyngeal Carcinoma (NPC)
NCT00078546
Efficacy Study of Antiseptic Preoperative Scrubs in Prevention of Postoperative Infections
NCT00290290
Administration of Virus-Specific Cytotoxic T-Lymphocytes
NCT00590083
Growth Hormone and GnRH Agonist in Adolescents With Acquired Hypothyroidism
NCT00206375
Blood T-Cells and EBV Specific CTLs Expressing GD-2 Specific Chimeric T Cell Receptors to Neuroblastoma Patients
NCT00085930
Fludarabine, Cyclophosphamide, and Alemtuzumab in Treating Patients With Recurrent or Metastatic Renal Cell Carcinoma (Kidney Cancer) Undergoing Allogeneic Stem Cell Transplantation
NCT00073879
Anti-Human CD45 Monoclonal Antibodies in Patients With Advanced Leukemia Prior to Allogeneic Stem Cell Transplantation
NCT00057005
Leptin for Abnormal Lipid Kinetics in HIV Lipodystrophy Syndrome
NCT01511016
Corticosteroids in Postoperative Critically Ill Neonates With Low Cardiac Output Syndrome With Congenital Heart Disease
NCT00590018
Treatment of B-CLL With Human IL-2 and CD40 Ligand and Plasmid Gene Modified Autologous Tumor Cells
NCT00078520
Treatment of Chronic Lymphocytic B-Leukemia With IL-2 and CD-40 Autologous Tumor Cells
NCT00058786
Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation of Patients With Hematological Diseases
NCT00056966
The Role of Amylin and Glucagon in T1DM
NCT00206258
Rituxan + BEAM and Auto Stem Cell Transplant for High Risk Lymphoma or Hodgkin's Disease
NCT01702961
Monoclonal Antibody Conditioning for Allogeneic Stem Cell Transplantation of Patients With Inherited Metabolic Storage Diseases
NCT00056979
Use of Rft5-Dga to Deplete Alloreactive Cells for Pts With Fanconi Anemia After Haploidentical SCT
NCT00586274
Allogeneic Stem Cell Transplant for Patients With Severe Aplastic Anemia
NCT00578903
A Comparison of Renal Perfusion in Thoracoabdominal Aortic Aneurysm (TAAA) Repair
NCT00691756
PS-341 Followed by Removal of Prostate for Those With Prostate Cancer
NCT00425503
Preventing Overweight in USAF Personnel: Minimal Contact Program
NCT00417599
Total-Body Irradiation, Fludarabine, and Alemtuzumab Followed By Stem Cell Transplant in Treating Patients With Myeloproliferative Disorder, MS, AML, or CML
NCT00069992
Intrathecal Gemcitabine to Treat Neoplastic Meningitis, IT Gemcitabine
NCT00074607
Treatment of Resistant Langerhans Cell Histiocytosis With ENBREL
NCT00048373
A Pharmacokinetic Study of Valacyclovir in Pediatric Oncology Patients
NCT00042328
T-Lymphocytes in Treating Patients With Epstein-Barr Virus-Positive Nasopharyngeal Cancer, NPC
NCT00609219
Antibody Conditioning Regimen For Allogeneic Donor Stem Cell Transplantation Of Patients With Fanconi Anemia
NCT00590460
Encouraging Calcium Absorption and Bone Formation During Early Puberty
NCT00022867
Safety and Effectiveness of Soy Phytoestrogens to Prevent Bone Loss
NCT00665860
Photorefractive Keratectomy for Severe Anisometropia and Isoametropia Associated With Amblyopia
NCT03610997
Prevention and Treatment of Epstein-Barr Virus (EBV) Lymphoma Following a Solid Organ Transplant Using EBV Specific Cytotoxic T Lymphocytes (CTLs).
NCT00058604
Oral Magnesium Pidolate, Hemoglobin SC Disease, MG Pidolate
NCT00040456
Stem Cell Transplantation for Patients With Graft Failure Following an Allogeneic Transplant, Using Identical or Near Identical Donors and Less Toxic Conditioning With CAMPATH 1H
NCT00048399
Efficacy Study of an Educational Program for Decision Support for Breast Cancer
NCT00473096
Bone Marrow Transplant From Donor Using Less Toxic Conditioning for Patient With High Risk Hemoglobinopathies
NCT00040417
Bone Marrow Transplant From Related Donor for Patients With High Risk Hemoglobinopathies
NCT00040469
Stem Cell Transplant for Hematologic Diseases
NCT00058825
Evaluating the Use of RFT5-dgA to Deplete Alloreactive Cells Prior to Haploidentical Stem Cell Transplantation
NCT00586547
Stem Cell Transplant for Patients With Blood Malignancy Using Donors and Less Toxic Chemotherapy With CAMPATH 1H
NCT00048412
Study of Systemic and Spinal Chemotherapy Followed by Radiation for Infants With Brain Tumors
NCT00042367
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 173 |
| Phase 2 | 59 |
| Phase 3 | 13 |
| Phase 4 | 46 |
Therapeutic Areas
What is open in the Baylor College of Medicine pipeline
93 recruiting of 616 indexed (15% open); 376 completed (61%).
Phase mix: 59 late (III/IV) vs 232 early (I/II) (early-phase heavy).
Top condition: Non-Hodgkin Lymphoma (7 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Baylor College of Medicine: open-pipeline peers nationwide
Peers matched on 616 registered trials and 15% open enrollment, not the therapeutic-area sidebar.
Baylor College of Medicine sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 616 trials (± recruiting share)
- University of Southern California · 617 trials · 16% recruiting
- US Department of Veterans Affairs · 632 trials · 0% recruiting
- University of Rochester · 636 trials · 15% recruiting
- Janssen Research & Development · 593 trials · 11% recruiting
Sponsors near 15% open enrollment (± trial volume)
- Stanford University · 15% recruiting · 1,744 trials
- Baylor University · 15% recruiting · 33 trials
- Cornell University · 15% recruiting · 66 trials
- 59th Medical Wing · 15% recruiting · 20 trials
Related
What to do with this Baylor College of Medicine page
616 registered trials is a research-attention snapshot, not an endorsement of Baylor College of Medicine or any single study.
- 93 of Baylor College of Medicine's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Non-Hodgkin Lymphoma is the condition Baylor College of Medicine studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Non-Hodgkin Lymphoma trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Baylor College of Medicine pipeline card: 616 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.